The former vice president of a Carmel Valley pharmaceutical company pleaded guilty Friday to a federal securities fraud count.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ ... Investors looking for promising ...

George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges. BioWorld ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted ... guilty today to a federal securities fraud count for insider trading. George Demos, 64, formerly of Acadia Pharmaceuticals ...

Editor’s note: This story has been updated to correct the individual who admitted to insider trading. SAN DIEGO (FOX 5/KUSI) — The former vice president of Acadia Pharmaceuticals Inc ...

In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $28.00. The company’s ...

Citizens JMP lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $39. Acadia reported Q4 financial results largely consistent with consensus estimates and provided 2025 ...

The former vice president of a San Diego-based pharmaceutical company pleaded guilty Friday to a federal securities fraud count for insider trading ... 64, formerly of Acadia Pharmaceuticals ...